ArticleFrontiers in medicine2026
Dosimetric and clinical outcomes of stereotactic body radiotherapy for primary lung cancer: isocenter-based vs. volume-based prescription.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Stereotactic body radiotherapy (SBRT) has emerged as the standard treatment modality for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC). However, the optimal dose prescription method for SBRT remains controversial, with traditional isocenter-based prescriptions increasingly being replaced by volume-based prescriptions in clinical practice. Methods: We retrospectively analyzed 88 consecutive patients with T1-T2aN0M0 NSCLC who were treated with SBRT between 2015 and 2024 at our institution. Patients were categorized based on prescription method, and their dosimetric and clinical outcomes were compared. Results: Dosimetric evaluation results were significantly superior with volume-based prescriptions, demonstrating improved planning target volume (PTV) coverage (95% volume), and higher minimum, mean, and maximum doses ( Conclusion: Volume-based SBRT prescriptions enhance both dosimetric quality and clinical efficacy without increasing pulmonary toxicity. Our results highlight volume-based prescription as a preferred strategy for SBRT in patients with early-stage NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.